AstraZeneca: UBS maintains buy rating
(CercleFinance.com) - UBS on Thursday reiterated its buy rating on AstraZeneca shares, with a target of 8,000 pence, following the bio-pharma group's publication of additional data concerning its anti-Covid vaccine.
The company announced this morning that its Covid-19 vaccine achieved 76% efficacy in phase III clinical trials, down from the previously reported 79%.
AstraZeneca justified the downward revision by the occurrence of 49 additional cases of symptomatic Covid infections in its study, which included more than 32,000 patients.
"The full primary analysis of the US pIII trial of AZD1222 supports the interim results. There does not seem to be a data integrity issue", analysts said.
However, they note that the level of efficacy of AstraZeneca's vaccine against new mutations of the coronavirus (the "variants"), is still to be determined.
The share is up about 0.5% at lunchtime on Thursday.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The company announced this morning that its Covid-19 vaccine achieved 76% efficacy in phase III clinical trials, down from the previously reported 79%.
AstraZeneca justified the downward revision by the occurrence of 49 additional cases of symptomatic Covid infections in its study, which included more than 32,000 patients.
"The full primary analysis of the US pIII trial of AZD1222 supports the interim results. There does not seem to be a data integrity issue", analysts said.
However, they note that the level of efficacy of AstraZeneca's vaccine against new mutations of the coronavirus (the "variants"), is still to be determined.
The share is up about 0.5% at lunchtime on Thursday.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.